Quizartinib and AC886 had concentration-dependent inhibitory activity on the FLT3 signaling pathway in the AML cell line MV4-11, which harbors the FLT3-ITD mutation (Figure 2A). The gene discussed is FLT3; the disease is acute myeloid leukemia.